La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

SonoScape Medical Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Kunxiang Wu

Amministratore delegato

CN¥900.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Returns On Capital Signal Tricky Times Ahead For SonoScape Medical (SZSE:300633)

Aug 18

Is SonoScape Medical Corp. (SZSE:300633) Expensive For A Reason? A Look At Its Intrinsic Value

Jul 17

An Intrinsic Calculation For SonoScape Medical Corp. (SZSE:300633) Suggests It's 41% Undervalued

Feb 28

AMMINISTRATORE DELEGATO

Kunxiang Wu (61 yo)

no data

Mandato

CN¥900,000

Compensazione

Mr. Kunxiang Wu is General Manager & Director of SonoScape Medical Corp.

SonoScape Medical Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

SonoScape Medical Corp., Annual General Meeting, May 10, 2024

SonoScape Medical Corp., Annual General Meeting, May 10, 2024

Less than half of directors are independent

SonoScape Medical Corp. Approves Board Elections

Insufficient new directors

SonoScape Medical Corp. Announces Executive Election

Recent updates

Returns On Capital Signal Tricky Times Ahead For SonoScape Medical (SZSE:300633)

Is SonoScape Medical Corp. (SZSE:300633) Expensive For A Reason? A Look At Its Intrinsic Value

Now 21% overvalued

Investor sentiment deteriorates as stock falls 15%

SonoScape Medical Corp. to Report First Half, 2024 Results on Aug 29, 2024

Does SonoScape Medical (SZSE:300633) Have A Healthy Balance Sheet?

Dividend increased to CN¥0.32

SonoScape Medical Corp. 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 29 May 2024

Pinning Down SonoScape Medical Corp.'s (SZSE:300633) P/E Is Difficult Right Now

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 7.8% to CN¥50.15

Full year 2023 earnings: EPS misses analyst expectations

SonoScape Medical Corp., Annual General Meeting, May 10, 2024

SonoScape Medical Corp., Annual General Meeting, May 10, 2024

SonoScape Medical Corp. to Report Q1, 2024 Results on Apr 27, 2024

We Think SonoScape Medical (SZSE:300633) Can Manage Its Debt With Ease

An Intrinsic Calculation For SonoScape Medical Corp. (SZSE:300633) Suggests It's 41% Undervalued

Less than half of directors are independent

Investor sentiment improves as stock rises 17%

SonoScape Medical Corp. Approves Board Elections

SonoScape Medical Corp. to Report Fiscal Year 2023 Results on Apr 12, 2024

Price target decreased by 8.0% to CN¥57.34

Now 21% undervalued

SonoScape Medical Corp. (SZSE:300633) announces an Equity Buyback for CNY 120 million worth of its shares.

SonoScape Medical Corp. (SZSE:300633) announces an Equity Buyback for CNY 120 million worth of its shares.

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 7.4% to CN¥62.43

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

SonoScape Medical Corp. to Report Q2, 2023 Results on Aug 23, 2023

SonoScape Medical Corp. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 08 June 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment improved over the past week

Price target increased to CN¥71.16

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.076 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.29 (vs CN¥0.18 in 2Q 2021)

Investor sentiment improved over the past week

Sonoscape Medical Corp. Announces Final Dividend on Share A for 2021, Payable on July 15, 2022

SonoScape Medical Corp. Approves 2021 Profit Distribution Plan

SonoScape Medical Corp. Proposes Final Cash Dividend for 2021

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

SonoScape S-Fetus 4.0 Release to Simplify Sonography Process

SonoScape Medical Corp. Receives FDA 510(k) Clearance for HD-550 Endoscopy system

Third quarter 2021 earnings released: EPS CN¥0.076 (vs CN¥0.004 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.085 in 2Q 2020)

SonoScape Obtains CE-Mark for Its Linear Array Echoendoscope EG-UC5T

Price target increased to CN¥30.86

Sonoscape Medical Corp. Proposes Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.02 loss in 1Q 2020)

New 90-day low: CN¥20.36

SonoScape Medical Corp. Announces Executive Election

New 90-day low: CN¥21.50

New 90-day low: CN¥25.16

Third quarter earnings released

SonoScape Medical Corp. announced that it expects to receive CNY 1.2 billion in funding

New 90-day low: CN¥27.25

Analysts lower EPS estimates to CN¥0.40

Earnings released

New 90-day low - CN¥30.72

SonoScape Medical Corp. to Report First Half, 2020 Results on Aug 26, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione